GPT and acute lymphoblastic leukemia: Consistent with our results, Ladas et al. (Ladas et al., 2010), in their study to evaluate the safety and feasibility of silymarin over a 28- and 56-Day period for the treatment of hepatotoxicity in children with ALL who were receiving maintenance-phase chemotherapy, reported that their studied patients did not show statistically significant changes in mean ALT, AST, and bilirubin at Day 28, but at Day 56, the silymarin-treatment group had a significantly lower AST and a trend toward a significantly lower ALT.